- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 May 2025 | 12 May 2025 |
| This is to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, the 28 th day of May 2025 inter-alia to consider and approve the Audited Financial Results for the quarter and year ended 31 st March, 2025 and other items of business and related matters. Please further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time-to-time TRADING WINDOW for dealing in the securities of the Company by the Employee(s), connected persons and their immediate relatives will be closed from 13 th May, 2025 till 48 hours after the declaration of financial results Audited Financial Results for the quarter and year ended 31st March, 2025 Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 (As Per BSE Announcement Dated on: 28/05/2025) | ||
| Board Meeting | 12 Feb 2025 | 30 Jan 2025 |
| NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve the unaudited financial results for the quarter and nine months ended 31st December 2024 and 3rd Interim Dividend if any Unaudited Financial Results for the quarter and nine months ended December 31, 2024 (As Per Bse Announcement Dated on 12.02.2025) | ||
| Board Meeting | 12 Nov 2024 | 28 Oct 2024 |
| Quarterly Results & Interim Dividend Outcome of Board Meeting Declared second interim dividend of Rs.1.50 (Rupees one and fifty paise only) (75%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2024-25. The date for taking on record of its shareholders eligible for the purpose of payment ofsecond interim dividend i.e., record date is fixed as Monday, the 25th day of November 2024. The payment of said interim dividend will start from 2nd December 2024. (As Per BSE Announcement Dated on 12.11.2024) | ||
| Board Meeting | 12 Aug 2024 | 26 Jul 2024 |
| NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve the Un-audited Financial Results for the quarter ended June 30 2024 and declaration of Interim Dividend for FY 2024-25 if any Unaudited Financial Results for the quarter ended 30th June 2024 along with Limited Review Report (As Per BSE Announcement Dated on 12.08.2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.